Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing.

Journal of clinical laboratory analysis - 1 Jul 2020

Zhou Li, Li Rui, Zhang Runling, Peng Rongxue, Chen Kun, Gao Peng, Zhang Jiawei, Zhang Rui, Li Jinming

Abstract excerpt

BACKGROUND: To meet the requirements of the rapidly progressing genetic testing technologies in clinical laboratories, assuring the quality of genetic tests by utilizing appropriate quality control materials is of paramount importance. The CRISPR/Cas9 technology was used to prepare quality control materials because genome-edited human cell lines are one of the major resources for quality control materials....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Thalassemia
Share to CRISPR-Associated Protein 9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CRISPR-Cas Systems

Share to Electroporation

Share to Gene Editing

Share to Quality Control

Share to RNA, Guide, CRISPR-Cas Systems

Share to Whole Genome Sequencing

Source

Open in PubMed Open full text

Identifiers

PMID: 32118319
DOI: 10.1002/jcla.23256
PMCID: PMC7370731

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing.PMID 32118319Read ↗

Therapeutic promise of CRISPR-Cas9 gene editing in sickle cell disease and β-thalassemia: A current reviewSemantic proximity Read ↗

Gene Editing for Inherited Red Blood Cell DiseasesSemantic proximity Read ↗

Development of a CRISPR-Cas9-Based Cellular Model for SGCB Gene Mutation: A Platform for Investigating Gene Therapy Strategies in LGMD2ESemantic proximity Read ↗

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-ThalassemiaSemantic proximity Read ↗

Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/CRISPR-Associated Endonuclease Cas9-Mediated Homology-Independent Integration for Generating Quality Control Materials for Clinical Molecular Genetic Testing.Semantic proximity Read ↗

The Italian breakthrough in CRISPR trials for rare diseases: a focus on beta-thalassemia and sickle cell disease treatmentSemantic proximity Read ↗

Efficient CRISPR-Cas9-based genome editing of β-globin gene on erythroid cells from homozygous β039-thalassemia patientsSemantic proximity Read ↗

CRISPR/Cas9, a promising approach for the treatment of β-thalassemia: a systematic review.Semantic proximity Read ↗

Efficient repair of human homozygous genetic mutation by CRISPR/Cas9 mediated interlocus gene conversionSemantic proximity Read ↗

Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology.Semantic proximity Read ↗

Efficient ssODN-Mediated Targeting by Avoiding Cellular Inhibitory RNAs through Precomplexed CRISPR-Cas9/sgRNA Ribonucleoprotein.Semantic proximity Read ↗

Investigating the Efficacy of the CRISPR/Cas9 Gene-Editing System for Targeting the HBB FSC 36-37 (-T) Mutation Locus in Hematopoietic Stem Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.